Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,401–1,500 of 2,576
Noelker, C., Hampel, H. J., & Dodel, R. C. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256398 · Cited by 32
Scherberich, J. E., Kellermeyer, M., Ried, C., & Hartinger, A. (2005) · PubMed · Cited by 42
Early diagnostic indices for the prevention of Alzheimer's disease
Soininen, H. S., & Scheltens, P. (1998) · Annals of Medicine · doi:10.3109/07853899809002604 · Cited by 33
The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome
Matsuoka, Y., Andrews, H., Becker, A. G., Gray, A. J., Mehta, P. D., Sano, M. C., Dalton, A. J., & Aisen, P. S. S. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181aba61e · Cited by 31
Transgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis
Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00198.x · Cited by 30
Chu, T., Tran, T., Yang, F., Beech, W., Cole, G. M., & Frautschy, S. A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01161-2 · Cited by 29
Dvir, E., Friedman, J. E., Lee, J. Y., Koh, J., Younis, F. M., Raz, S., Shapiro, I., Hoffman, A., Dahan, A., Rosenberg, G., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103184 · Cited by 32
“This mutation causes increases in secreted A 42 and A 40 in the brain, and the mice develop amyloid plaques and progressive cognitive deficits (Citron et al., 1994; Hsiao et al., 1996; Scheuner et al., 1996).”
BackgroundThe search for antecedent biomarkers of Alzheimer's disease
Fagan, A. M., Csernansky, C. A., Morris, J. C., & Holtzman, D. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8404 · Cited by 31
“A very recent study has demonstrated robust decreases in CSF A β 42 levels in presymptomatic individuals carrying PS1 mutations [83], whereas plasma concentrations of A β 42 have been reported to be elevated in presymptomatic carriers of FAD mutations [109].”
Localization and Possible Functions of Presenilins in Brain
McGeer, P. L., Kawamata, T., & McGeer, E. G. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.1.1 · Cited by 30
Small, D. H. (1998) · Neurochemical Research · doi:10.1023/a:1022471729291 · Cited by 40
Transgenic models of neurodegenerative diseases
Lee, M. K., Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80099-7 · Cited by 34
Different effects of Alzheimer-associated mutations of presenilin 1 on its processing
Murayama, O., Honda, T., Mercken, M. H., Murayama, M., Yasutake, K., Nihonmatsu, N., Nakazato, Y., Michel, G., Song, S., Sato, K., et al. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00417-5 · Cited by 30
A non-human primate model of familial Alzheimer’s disease
Sato, K., Sasaguri, H., Kumita, W., Inoue, T., Kurotaki, Y., Nagata, K., Mihira, N., Sato, K., Sakuma, T., Yamamoto, T., et al. (2020) · doi:10.1101/2020.08.24.264259 · Cited by 29
Love, M. N., Clark, D. G., Cochran, J. N., Beste, K. A. D., Geldmacher, D., Benzinger, T. L. S., Gordon, B. A., Morris, J. C., Bateman, R. J., & Roberson, E. D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.020 · Cited by 30
“In vitro studies suggest that pathogenic mutations within PSEN1 increase the ratio of 4 Aβ42, which is more amyloidogenic, to Aβ40 (Duff et al., 1996; Scheuner et al., 1996; KumarSingh et al., 2006).”
Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer’s Disease
Robinson, R. A. S., Amin, B., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_2 · Cited by 32
Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
Perrone, F., Bjerke, M., Hens, E., Sieben, A., Timmers, M., Roeck, A. D., Vandenberghe, R. R., Sleegers, K., Martin, J., Deyn, P. P. D., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00676-5 · Cited by 31
“Aβ1–42 levels have been used for the pathological classification of AD mutations, both in vivo and in vitro [20].”
MethodHu, Y., Boonstra, J. T., McGurran, H., Stormmesand, J., Sluiter, A. A., Balesar, R. A., Verwer, R. W. H., Swaab, D. F., & Bao, A. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12729 · Cited by 30
Beta-amyloid toxicity modifier genes and the risk of Alzheimer's disease.
Rosenthal, S. L., Wang, X., Demirci, F. Y., Barmada, M. M., Ganguli, M., López, O. L., & Kamboh, M. I. (2012) · Europe PMC (PubMed Central) · Cited by 31
Does Aβ 42 Have a Function Related to Blood Homeostasis?
Hardy, J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9221-9 · Cited by 31
Self-citationDobričić, V., Stefanova, E. D., Janković, M. Z., Gurunlian, N., Novaković, I. V., Hardy, J., Kostić, V., & Guerreiro, R. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.007 · Cited by 30
“…increase the secretion of A 42, increase the ratio of A 42/A 40 or produce a more fibrillogenic form of A (Younkin, 1998) thus favoring amyloid deposition in the brain which provides supportive evidence for the amyloid cascade hypothesis of AD (Hardy and Higgins, 1992; Scheuner et al., 1996).”
Self-citationParisiadou, L., Fassa, A., Fotinopoulou, A., Bethani, I., & Efthimiopoulos, S. (2004) · Neurodegenerative Diseases · doi:10.1159/000080984 · Cited by 37
Chang, C.-C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082139 · Cited by 33
Lahiri, D. K., & Ge, Y. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1329.039 · Cited by 28
Children of Persons With Alzheimer Disease: What Does the Future Hold?
Jarvik, L. F., LaRue, A. A., Blacker, D., Gatz, M., Kawas, C. H., McArdle, J. J., Morris, J. C., Mortimer, J. A., Ringman, J. M., Ercoli, L. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653ac · Cited by 33
Brain pathology in three subjects from the same pedigree with presenilin-1 (PSEN1) P264L mutation
Martikainen, P., Pikkarainen, M., Pöntynen, K., Hiltunen, M. O., Lehtovirta, M., Tuisku, S., Soininen, H. S., & Alafuzoff, I. I. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01046.x · Cited by 30
Pomara, N., & Doraiswamy, P. M. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00380-8 · Cited by 28
Rueeger, H., Lueoend, R. M., Machauer, R., Veenstra, S. J., Jacobson, L. H., Staufenbiel, M., Desrayaud, S., Rondeau, J., Möbitz, H., & Neumann, U. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.071 · Cited by 30
Manzano-Crespo, M., Atienza, M., & Cantero, J. L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0174-8 · Cited by 31
Mutant presenilin (A260V) affects Rab8 in PC12D cell
Kametani, F., Usami, M., Tanaka, K., Kume, H., & Mori, H. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00176-1 · Cited by 29
Brewer, G. J. (1997) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815241 · Cited by 32
“In AD subjects with mutations in the presenilin genes 1 or 2, plasma A[3 levels were elevated compared to controls (Scheuner et al., 1996).”
BackgroundYeh, H., & Tsai, S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.03.049 · Cited by 28
“Studies of biochemical markers suggest that elevations of plasma Abeta1–42 peptide occur early in presenile FAD subjects [25].”
BackgroundLeutz, S., Steiner, B., Marques, C. A., Haass, C., Müller, W. E., & Eckert, A. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:3:189 · Cited by 32
“In contrast to APPsw, other FAD-related APP mutations, e.g., V717, or mutations in PS1/2 selectively increase the levels of the longer and more amyloidogenic form Aβ1-42 (Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997).”
ResultGene identification in Alzheimer’s disease
Saunders, A. M. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.3.239 · Cited by 34
Presenilins Upregulate Functional K+Channel Currents in Mammalian Cells
Malin, S. A., Guo, W., Jafari, G., Goate, A., & Nerbonne, J. M. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0167 · Cited by 28
Basun, H., Nilsberth, C., Eckman, C. B., Lannfelt, L., & Younkin, S. G. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000063605 · Cited by 31
“The strengths with this study are the well-diagnosed patients and an extensively used Aß assay with small variations [Suzuki et al., 1994; Scheuner et al., 1996] and that the plasma concentrations of tacrine have been monitored.”
MethodSelf-citationBlanchard, V., Czech, C., Bonici, B., Clavel, N., Gohin, M., Dalet, K., Revah, F., Pradier, L., Impérato, A., & Moussaoui, S. M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00231-x · Cited by 29
Artificial gravity as a countermeasure in long-duration space flight
Lackner, J. R., & DiZio, P. A. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001015)62:2<169::aid-jnr2>3.0.co;2-b · Cited by 42
Global Energy Metabolism Deficit in Alzheimer Disease Brain
Patel, V., Mill, J. S., Okonkwo, O. C., Salamat, S. M., Li, L., & Raife, T. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.91 · Cited by 28
“The discovery of gene mutations related to familial AD that cause production of beta-amyloid variants that clump easily support the amyloid hypothesis (4, 5).”
Kumar, A., & Singh, T. R. (2016) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-016-0144-0 · Cited by 27
Sharma, D., Otto, G. P., Warren, E. C., Beesley, P. W., King, J., & Williams, R. S. B. (2019) · Autophagy · doi:10.1080/15548627.2019.1586245 · Cited by 29
Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28
Membrane lipid remodeling modulates γ-secretase processivity
Dawkins, E., Derks, R. J. E., Schifferer, M., Trambauer, J., Winkler, E., Simons, M., Paquet, D., Giera, M. A., Kamp, F., & Steiner, H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103027 · Cited by 32
Rabe, S., Reichwald, J., Ammaturo, D., de Strooper, B., Saftig, P., Neumann, U., & Staufenbiel, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07412.x · Cited by 28
P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1
Korade, Ž., Yan, C., Portugal, C. F., Kim, T.-W., Saragovi, H. U., Sisodia, S. S., Mirnics, K., & Schor, N. F. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.06.004 · Cited by 32
Gong, P., Vetrivel, K. S., Nguyen, P. D., Meckler, X., Cheng, H., Kounnas, M. Z., Wagner, S. L., Parent, A., & Thinakaran, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132613 · Cited by 30
Erythrocytes as Potential Link between Diabetes and Alzheimer’s Disease
Carelli‐Alinovi, C., & Misiti, F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00276 · Cited by 26
“In last years, Aβwas found in peripheral plasma blood (Scheuner et al., 1996; Mehta et al., 2000; van Oijen et al., 2006; GraffRadford et al., 2007) where it interacts with RBC, leading to impairment of its function (Mattson et al., 1997; Clementi et al., 2007; Mohanty et al., 2008), suggesting…”
BackgroundLahiri, D. K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1329.035 · Cited by 27
Dowjat, W. K., Kuchna, I., Wısnıewskı, T., & Węgiel, J. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6105 · Cited by 28
“Consistent with previous reports [2,4,28,37] both mutations were associated with increased production and secretion of Aβ42.”
BackgroundResultApoptosis in Neurodegenerative Diseases
Nishimoto, I., Okamoto, T., Giambarella, U., & Iwatsubo, T. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)61064-9 · Cited by 27
Tomidokoro, Y., Harigaya, Y., Matsubara, E., Ikeda, M., Kawarabayashi, T., Okamoto, K., & Shoji, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01443-9 · Cited by 32
Lévesque, L., Annaert, W., Craessaerts, K., Mathews, P. M., Seeger, M., Nixon, R. A., Van Leuven, F., Gandy, S., Westaway, D., St George-Hyslop, P., et al. (1999) · Molecular Medicine · doi:10.1007/bf03401981 · Cited by 21
Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko, D. R. (1998) · PubMed · Cited by 30
The expanding role of CDR1‐AS in the regulation and development of cancer and human diseases
Azari, H., Mousavi, P., Karimi, E., Sadri, F., Zarei, M., Rafat, M., & Shekari, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29950 · Cited by 29
“Mutations in the amyloid precursor genes such as presenilin1 and presenilin2, as well as the Apolipoprotein E (APOE) gene, are the major genetic factors that have been studied in this disease (Kelleher & Shen, 2017; Lanoiselée et al., 2017; Scheuner et al., 1996).”
BackgroundSelenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer’s Disease
Barbosa, F. A. R., Canto, R. F. S., Teixeira, K. F., de Souza, A. S., de Oliveira, A. S., & Braga, A. L. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220224161454 · Cited by 26
Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease
Susmitha, G., & Kumar, R. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109478 · Cited by 28
Structural and mechanistic commonalities of amyloid-β and the prion protein
Dias, B. D. C., Jovanovic, K., Gonsalves, D., & Weiss, S. F. T. (2011) · Prion · doi:10.4161/pri.5.3.17025 · Cited by 31
Condron, M. M., Monien, B. H., & Bitan, G. (2008) · The Open Biotechnology Journal · doi:10.2174/1874070700802010087 · Cited by 28
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26
Ca2+ enhances Aβ polymerization rate and fibrillar stability in a dynamic manner
Brännström, K., Öhman, A., Lindhagen‐Persson, M., & Olofsson, A. (2012) · Biochemical Journal · doi:10.1042/bj20121583 · Cited by 29
New Genes and New Insights from Old Genes: Update on Alzheimer Disease
Ringman, J. M., & Coppola, G. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429179.21977.a1 · Cited by 36
Maleki, A. F., Cisbani, G., Plante, M.-M., Préfontaine, P., Laflamme, N., Gosselin, J., & Rivest, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01893-3 · Cited by 26
The genetic causes of neurodegenerative diseases
Hardy, J. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3115 · Cited by 26
Self-citationKurata, T., Kawarabayashi, T., Murakami, T., Miyazaki, K., Morimoto, N., Ohta, Y., Takehisa, Y., Nagai, M., Ikeda, M., Matsubara, E., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21352 · Cited by 26
“…Research 85:2246–2252 (2007) ' 2007 Wiley-Liss, Inc. mutations of b-amyloid precursor protein (bAPP), PS-1, and PS-2 increase the extracellular concentrations of Ab42 and protofibril Ab, they are likely to be initiating factors in the evolution of all types of AD (Scheuner et al., 1996).”
BackgroundPresenilin Function in APP Processing
Annaert, W. G., Cupers, P., Säftig, P., & Strooper, B. D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06917.x · Cited by 33
Small‐molecule inducers of Aβ‐42 peptide production share a common mechanism of action
Bettayeb, K., Oumata, N., Zhang, Y., Luo, W., Bustos, V., Galons, H., Greengard, P., Meijer, L., & Flajolet, M. (2012) · The FASEB Journal · doi:10.1096/fj.12-212985 · Cited by 30
Ge, Y., Ghosh, C., Song, W., Maloney, B., & Lahiri, D. K. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02608.x · Cited by 26
“The majority of APP is cleaved at Ab16 by a-secretase to generate soluble amino-terminal derivatives of APP (sAPPa).”
BackgroundGenetics of neurological disorders
Faghihi, M. A., Mottagui‐Tabar, S., & Wahlestedt, C. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.317 · Cited by 26
Yang, Y., & Gao, Y. Q. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp502169b · Cited by 27
Autopsy-Confirmed Familial Early-Onset Alzheimer Disease Caused by the L153V Presenilin 1 Mutation
Janssen, J. C., Lantos, P. L., Fox, N. C., Harvey, R. J., Beck, J. A., Dickinson, A., Campbell, T. A., Collinge, J., Hanger, D. P., Cipolotti, L., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.6.953 · Cited by 27
Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment
Liu, W. W., Todd, S., Craig, D., Passmore, A. P., Coulson, D. T. R., Murphy, S., Irvine, G. B., & Johnston, J. A. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000110739 · Cited by 31
Pathways to Primary Neurodegenerative Disease
Hardy, J. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.8.835 · Cited by 26
Self-citationImmunoreactivity of Presenilin-1 and Tau in Alzheimer's Disease Brain
Hendriks, L., Jonghe, C. D., Lübke, U., Woodrow, S., Vanderhoeven, I., Boons, J., Cras, P. P., Martin, J., & Broeckhoven, C. V. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6739 · Cited by 26
Tamaoka, A., Fraser, P. E., Ishii, K., Sahara, N., Ozawa, K., Ikeda, M., Saunders, A. M., Komatsuzaki, Y., Sherrington, R., Lévesque, G., et al. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00044-8 · Cited by 30
Alzheimer's β‐amyloid vasoactivity: identification of a novel β‐amyloid conformational intermediate
Crawford, F., Soto, C., Suo, Z., Fang, C., Parker, T., Sawar, A., Frangione, B., & Mullan, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01170-3 · Cited by 26
Pharmacotherapy for Alzheimer's Disease: 2002
Knopman, D. S. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200303000-00009 · Cited by 29
Medical Plants and Nutraceuticals for Amyloid-β Fibrillation Inhibition
Witter, S., Witter, R., Vilu, R., & Samoson, A. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180066 · Cited by 25
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Sun, B., Chen, Y., Fan, D., Zhu, C., Zeng, F., & Wang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1810-y · Cited by 29
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
Presenilin mutations associated with fronto‐temporal dementia
Hutton, M. L. (2004) · Annals of Neurology · doi:10.1002/ana.20103 · Cited by 28
Self-citationNakagami, Y., Nishimura, S., Murasugi, T., Kubo, T., Kaneko, I., Meguro, M., Marumoto, S., Kogen, H., Koyama, K., & Oda, T. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02657-2 · Cited by 28
Ştefănescu, R., Stanciu, G. D., Luca, A., Caba, I.-C., Tamba, B.-I., & Mihai, C. T. (2019) · Molecules · doi:10.3390/molecules24061167 · Cited by 26
A novel presenilin 2 mutation (V393M) in early‐onset dementia with profound language impairment
Lindquist, S. G., Hasholt, L., Bahl, J. M. C., Heegaard, N., Andersen, B., Nørremølle, A., Stokholm, J., Schwartz, M., Batbayli, M., Laursen, H. B., et al. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02256.x · Cited by 25
Chrysamine G and its derivative reduce amyloid β-induced neurotoxicity in mice
Ishii, K., Klunk, W. E., Arawaka, S., Debnath, M. L., Furiya, Y., Sahara, N., Shoji, S., Tamaoka, A., Pettegrew, J. W., & Mori, H. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00915-1 · Cited by 30
Murayama, O., Murayama, M., Honda, T., Sun, X., Nihonmatsu, N., & Takashima, A. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00034-2 · Cited by 27
Sondag, C., & Combs, C. K. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-22 · Cited by 31
“Altered proteolysis of APP due to missense mutations in the APP gene results in increased production of Ab and increased accumulation of plaques [1-3].”
BackgroundNew approaches to diagnose and treat alzheimer's disease
Galasko, D. R. (2001) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(05)70075-6 · Cited by 29
γ-Secretase inhibitors and Alzheimer’s disease
Roberts, S. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00155-2 · Cited by 29
Morelli, L., Llovera, R. E., Ibendahl, S., & Castaño, E. M. (2002) · Neurochemical Research · doi:10.1023/a:1021679817756 · Cited by 27
“tosomal dominant forms of AD increase the steadystate ratio of Ab42–43/Ab40 in cultured cells and brains of transgenic mice carrying such mutants, (19,20) and (iv) Ab42–43 is highly toxic for neurons in culture either in fibrillar or non-fibrillar oligomeric forms (reviewed in 41).”
BackgroundDistinguishable effects of Presenilin-1 and APP717 mutations on amyloid plaque deposition
Ishii, K., Lippa, C. F., Tomiyama, T., Miyatake, F., Ozawa, K., Tamaoka, A., Hasegawa, T., Fraser, P. E., Shoji, S., Nee, L. E., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00216-0 · Cited by 25
Molecular Genetics of Alzheimer's Disease
Verdile, G., & Martin, R. (2008) · Nucleic acids and molecular biology · doi:10.1007/978-3-540-85383-1_8 · Cited by 26
“For many years, it was thought that PS1 mutations led to an increase in the more pathogenic Aβ42 or an increase in the Aβ42/40 ratio in vitro and in vivo (Scheuner et al. 1996; Borchelt et al. 1996; Lemere et al. 1996; Duff et al. 1996; Ishii et al. 1997; Citron et al. 1997; Xia et al. 1997; Murayama et al. 1999).”
BackgroundClarke, N. J., Crow, F. W., Younkin, S. G., & Naylor, S. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5357 · Cited by 32
Self-citationAlzheimer transgenic mouse models come of age
Duff, K. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01093-x · Cited by 28
Presenilin-1 is associated with Alzheimer's disease amyloid.
Wısnıewskı, T., Dowjat, W. K., Permanne, B., Palha, J. A., Kumar, A., Gallo, G., & Frangione, B. (1997) · Europe PMC (PubMed Central) · Cited by 27
Semagacestat's fall: where next for AD therapies?
(2013) · Nature Medicine · doi:10.1038/nm.3365 · Cited by 24
Picón-Pagès, P., Gutiérrez, D. A., Barranco-Almohalla, A., Crepin, G., Tajes, M., ILL‐Raga, G., Guix, F. X., Menéndez, S., Arumí-Uría, M., Vicente, R., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2739459 · Cited by 27
Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease
Salazar, A., Osse, A. M. L., Ortiz, A. A., Murtishaw, A. S., & Kinney, J. W. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.013 · Cited by 26
Brain amyloid β protein and memory disruption in Alzheimer’s disease
Xia, W. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7460 · Cited by 28
“Plasma Aβ42 is also elevated in patients carrying familial Alzheimer disease-linked mutations in PS1, PS2 and APP genes.(16) All autosomal dominant mutations have been found in PS and APP genes, and missense mutations in PS and APP genes account for the majority of early onset familial AD cases.”
Aβ Clearance, “hub” of Multiple Deficiencies Leading to Alzheimer Disease
Gallina, P., Scollato, A., Conti, R., Di Lorenzo, N., & Porfirio, B. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00200 · Cited by 25
“The imbalance between Aβ production and disposal mainly comes from overproduction in familial AD (Scheuner et al., 1996), while in sporadic cases it may be due to a reduced ability to clear (Mawuenyega et al.”
BackgroundWidespread white matter and conduction defects in PSEN1-related spastic paraparesis
Soosman, S. K., Joseph‐Mathurin, N., Braskie, M. N., Bordelon, Y. M., Wharton, D., Casado, M., Coppola, G., McCallum, H., Nuwer, M. R., Coutin-Churchman, P. E., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.030 · Cited by 24
“Introduction genes affect cleavage of APP (Scheuner et al., 1996) is supportive Alzheimer’s disease (AD) is the most common cause of neurodegenerative dementia, and an estimated 5.3 million Americans are currently afflicted by it (Alzheimer’s, 2015).”
BackgroundInfluentialWang, J., Qiao, F., Shang, S., Li, P., Chen, C., Dang, L., Jiang, Y., Huo, K., Deng, M., Wang, J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180140 · Cited by 27
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.